The software increased improvements in both reader sensitivity (8.0% on average) and specificity (6.9% on average). In addition, when reading tomosynthesis cases with the software, radiologists' reading times were reduced by more than 52.7%.

The software is trained to detect malignancies and determine the probability of malignant findings, providing radiologists with a "certainty of finding" score for each case and each detected lesion. These scores represent the algorithm's confidence that the detected soft-tissue densities and calcifications are malignant.

The software is available for use in Europe and is pending clearance by the U.S. Food and Drug Administration (FDA).